Abstract Burkholderia gladioli is a rare cause of bacteremia and sepsis in the absence of such predisposing factors as chronic granulomatous disease, cystic fibrosis, and immunosuppression. Little is known about B. gladioli infection in newborns. The aim of this study was to present the features of B. gladioli infection in newborns. Clinicopathological characteristics, patterns of antimicrobial susceptibility, predisposing factors, and outcomes of B. gladioli bloodstream infection were retrospectively analyzed in newborns treated between 2008 and 2011. During the 3-year study period, B. gladioli was isolated from the blood cultures of 14 patients (3.7 per 1,000 admissions). In all, 5 (35.7 %) of the 14 cases had a positive blood culture at the time of initial admission. Primary diagnoses in the neonates were severe major congenital anomalies, congenital leukemia, prematurity with respiratory distress syndrome, pneumonia, and parapneumonic pleural effusion. In total, 10 (71.4 %) of the patients underwent ≥2 invasive procedures. The overall in-hospital mortality rate was 21.4 %, whereas the mortality rate due to B. gladioli infection was 7 %.
Introduction
Burkholderia gladioli is a known plant pathogen and human infections due to this organism have rarely been reported. B. gladioli, formerly known as Pseudomonas marginata, is an aerobic, motile, non-fermenting gram-negative bacteria [9, 10, 13, 14] . The first report of B. gladioli infection in humans in 1989 described cystic fibrosis (CF) patients in which B. gladioli caused respiratory tract infection [2] . Then, this organism was reported as a cause of respiratory tract infections, septicemia, abscesses, osteomyelitis, keratitis, and adenitis in patients with CF and chronic granulomatous disease (CGD), transplant recipients, and in immunocompromised patients [13] . On the other hand, B. gladioli sepsis in the absence of such predisposing factors as CGD, CF, and immune dysfunction has not been well described in the literature. There is little known about B. gladioli infection in newborns. In our neonatal intensive care unit (NICU), B. gladioli was first isolated from a blood culture in 2008. Herein, we represent 14 newborns with B. gladioli sepsis that were hospitalized in our NICU during a 3-year period and their clinicopathological characteristics. To the best of our knowledge, this is the first report on B. gladioli sepsis in newborns.
Materials and methods

Patients and hospital settings
This study was conducted at Dr. Sami Ulus Children's and Maternity Hospital, a 416-bed tertiary care government hospital in Ankara, Turkey. Approximately 3,000 babies are born each year at the hospital. Newborn cardiac surgery has been performed at our hospital since December 2010. The NICU has 78 beds and serves approximately 1,300 admissions per year, including both inborn and outborn patients. Our NICU is composed of three separate units (NICU 1, 2, and 3). A retrospective computerized analysis of patients with sepsis caused by B. gladioli between August 2008 and August 2011 was performed. All patients with blood cultures positive for B. gladioli were included in the study.
Clinical characteristics
Gestational age, birth weight, gender, date of admission to the NICU, clinical characteristics, invasive procedures, antibiotic susceptibility, and treatment outcome were obtained from the computerized database, patients files, and followup forms. Neonatal sepsis was categorized as early onset (bloodstream infections that occurred ≤72 h after birth) and late onset (bloodstream infections that occurred >72 h after birth). Vaginal cultures of the neonate's mothers were also noted. Nosocomial sepsis was defined as bloodstream infections that occurred >72 h after NICU admission. The infection-specific mortality rate was defined as mortality within 14 days of a positive blood culture result. The overall in-hospital mortality rate was defined as mortality during hospitalization.
Ampicillin and gentamycin are the empirical antibiotics of choice in our NICU. Antibiotic treatment is changed in patients with suspected nosocomial infection until blood culture results are obtained. Meropenem was used during the study period for initial empirical antibiotic treatment in nosocomial sepsis cases. Vancomycin therapy was added if no response was achieved after 48-72 h of empirical antibiotic treatment of nosocomial sepsis. During antibiotic treatment of neonates, liver function, renal function, and acute-phase reactants were monitored weekly, as routine follow-up.
Bacterial isolates and antimicrobial susceptibility testing
All B. gladioli strains tested grew on eosin methylene blue agar on basal media at 35°C, but not at 42°C. All B. gladioli strains were indole-negative, failed to reduce nitrate to nitrite, were lysine decarboxylase-negative, ornithine decarboxylase-negative, and arginine dihydrolase-negative. B. gladioli strains were identified using a Phoenix Becton Dickinson system and antimicrobial susceptibility profiles were generated for each strain using conventional susceptibility panels (Becton Dickinson), according to the manufacturer's instructions [7] . Susceptibility of the bacterial isolates to antimicrobial agents was initially determined via the routine disk diffusion method and interpreted in accordance with National Committee for Clinical Laboratory Standards Clinical and Laboratory Standards Institute guidelines [3] .
Results
During the 3-year study period, 3,758 neonates were admitted to our NICU, of which 498 (13.2 %) had positive blood culture results. There were 35 different species of microorganism in the neonates with positive blood cultures. B. gladioli was observed for the first time in our NICU in 2008 and was subsequently isolated from the blood cultures of 13 additional cases, for a total of 14 cases of B. gladioli infection during the 3-year study period. The B. gladioli infection incidence rate was 0.37 %. The characteristics of the patients with B. gladioli infection were as follows: mean birth weight and gestational age were 2,300±780 g and 35±4 weeks, respectively; 50 % were born premature; the male/female ratio was 1:1; 71 % (n010) were delivered via Caesarean section. The clinical and laboratory features of the 14 cases are shown in Table 1 . In all, 5 (35.7 %) of the 14 cases had positive blood cultures at the time of NICU admission, whereas there were nine cases of nosocomial sepsis.
Cases with non-nosocomial sepsis All five cases of non-nosocomial infection had respiratory symptoms; one had an elevated C-reactive protein (CRP) level (6 mg L -1
) and three (21.4 %) (cases 2, 10, and 14) had earlyonset neonatal sepsis, of which two (cases 2 and 14) were inborn patients. One of these inborn neonates presented with pneumonia and the other presented with parapneumonic pleural effusion. The third case (case 10) of early-onset neonatal sepsis was referred from another hospital for cleft palate and respiratory symptoms on postnatal day 2 and was diagnosed as cat eye syndrome (partial trisomy 22q) in our NICU. Case 11 presented from home with respiratory symptoms at age of 59 days; the patient's gestational age was 29 weeks and she was diagnosed with acute lymphoblastic leukemia in our NICU. The remaining 17-day-old neonate (case 1) was referred from another hospital for congenital heart disease in first day of hospitalization. In all, 9 (64.3 %) of the 14 cases had nosocomial B. gladioli infection. The primary diagnoses in these neonates were Denys-Drash syndrome (DDS) (n01), muscular dystrophy (n01), diaphragmatic hernia (n01), prematurity with respiratory distress syndrome (n03), and severe congenital heart disease (n03) ( Table 1) . Whereas three cases (cases 4, 6, and 8) developed new pulmonary symptoms and one case (case 7) had fever during the hospitalization period, the other five cases (cases 3, 5, 9, 12, and 13) did not develop new symptoms, but only had an elevated CRP level during routine monitoring and B. gladioli-positive blood cultures. In total, seven neonates had an elevated CRP level at the time of bacteremia. All nine nosocomial B. gladioli infected patients were receiving antibiotic treatment at the time blood cultures were obtained. One neonate required intubation during the bacteremia period.
Invasive procedures
Among the 14 patients, 10 (71.4 %) underwent ≥2 invasive procedures. All nine neonates with nosocomial B. gladioli infection had a peripheral intravenous line and nasogastric catheter; two of the nine cases had an umbilical catheter, three had a central venous catheter, one had a peritoneal catheter, one had a thoracic catheter, seven were intubated, and three were treated with continuous positive airway pressure (CPAP) before positive blood cultures were obtained. In all, two of the five neonates with a positive blood culture at the time of initial admission only had a peripheral intravenous line; the other three did not undergo any invasive procedures.
Mortality rate
In total, 3 of the 14 patients died while hospitalized. Their primary diagnoses were DDS, prematurity with respiratory distress syndrome, and complete atrioventricular septal defect with pulmonary stenosis. The overall in-hospital mortality rate was 21.4 %. Follow-up blood cultures obtained 2-14 days after B. gladioli-positive blood culture results were negative in 13 of the14 cases; therefore, all the patients with B. gladioli infection were cured of the infection, except for one patient that died 14 days after B. gladioli-positive blood culture results were obtained. As such, the mortality rate due to B. gladioli infection was 7 %. The patient that died (case 10) had a severe congenital heart malformation (atrioventricular septal defect and pulmonary stenosis), had undergone surgery for congenital heart disease, and died 6 h after the surgery; blood culture was obtained from this patient 1 h post-surgery.
Antimicrobial susceptibility
The antimicrobial susceptibility of B. gladioli isolates is summarized in Table 2 . The antimicrobial agents most effective against B. gladioli were amikacin, gentamycin, imipenem, trimethoprim-sulfamethoxazole, ciprofloxacin, and ceftriaxone. All of the identified B. gladioli isolates were susceptible to amikacin, gentamycin, and imipenem. The susceptibility rate to ceftriaxone, ciprofloxacin, and trimethoprim-sulfamethoxazole was 100 %. The resistance rate of the B. gladioli isolates to aztreonam, ceftazidime, and colistin was 100 %. The resistance rate of the B. gladioli isolates to piperacillin-tazobactam was 71.4 %. In all the patients, B. gladioli isolates were susceptible to empirical antibiotic treatment, based on culture results. Antibiotic treatment details are given in Table 1 .
Investigation of suspected sources
The first case with a blood culture positive for B. gladioli occurred in July 2008, followed 26 months later by the second case in September 2010. The next three cases occurred later in 2010 and the remaining nine cases occurred in 2011. Concomitant B. gladioli infection was not seen in the same NICU, but there were seven concomitant cases in separate NICUs during the study period (Fig. 1) . In 2010 and in 2011, repeated environmental cultures were performed by our hospital infection control committee to determine the possible route of transmission or reservoir. Environmental samples were obtained from total parenteral nutrition solutions, humidifier water, tap water, tip of the water tap, and betadine solution, but no obvious transmission route or source of B. gladioli was identified.
Vaginal cultures were obtained from the mothers of the neonates with early neonatal sepsis, but none were positive for B. gladioli. None of the patients had a history of premature rupture of the amniotic membrane (>18 h before delivery). Furthermore, none of the neonates' mothers had an infectious disease during the antenatal period, and none of the outborn infants in the study were exposed to any identifiable source of B. gladioli.
Environmental surveys of other departments conducted by the hospital's infection control committee did not identify a source of B. gladioli. The infection control committee did not consider the surgical suite as a possible source of B. gladioli, as none of the patients that underwent surgical procedures during the study period had B. gladioli infection.
Discussion
B. gladioli is a rarely reported cause of sepsis, especially in the absence of such predisposing factors such as immunosuppression [2, 7, 9, 14] . B. gladioli is a known plant pathogen and has not been associated with human disease at the first reported studies [2, 7, 12] . All previously reported cases of B. gladioli infection are adults and children [1, 2, 7, 9, [12] [13] [14] . To the best of our knowledge, the present study is the first case series of B. gladioli infection in neonates. In the present study, eight of the neonate patients had severe major congenital anomalies, one had congenital leukemia, and three were born premature and had respiratory distress syndrome; these underlying critical diseases might have contributed to B. gladioli infection. Most of the neonates with B. gladioli infection presented with respiratory symptoms. Among the 14 neonates in the study, one presented with pneumonia and one presented with parapneumonic pleural effusion; therefore, respiratory symptoms might be the primary symptom of B. gladioli infections in newborns.
Boyanton et al. suggested that B. gladioli is most likely underreported by clinical microbiology laboratories due to its fastidious nature and difficulty differentiating it from members of the Burkholderia cepacia complex using currently available manual and automated identification systems [1] . Currently, there is no international gold standard for routine laboratory identification of clinically relevant Burkholderia spp. Unfortunately, we have only one automated system for routine use. It was reported that B. gladioli and B. cepacia complex organisms are differentiated based on the genetic diversity within the 16S rRNA gene [1, 5, 8, 15] .
Outbreaks or pseudo-outbreaks of B. cepacia have been documented in intensive care units and oncology units [6] . B. cepacia may contaminate and survive in aqueous hospital environments, including disinfectant agents and intravenous fluids, and may be transmitted via hospital sinks, hospital water used for oral and tracheostomy care, ventilator components, enteral feeding tubes, nasal sprays, and ultrasound gel [4, 11] . B. gladioli might be transmitted via similar routes, but this hypothesis must be verified via additional research. The first case of B. gladioli in our NICU occurred in 2008, and during the following 2 years, no other cases were observed; however, four new cases occurred in September 2010 and the remaining nine cases were observed in 2011 (Fig. 1) . Due to this unexpected outbreak, two environmental surveys were performed by our hospital infection control committee, but no obvious source was identified. In all, three of the neonates in the present study had early-onset neonatal sepsis. Although the mothers' vaginal cultures were reported as normal vaginal flora, it is not possible to eliminate the mothers as the source of B. gladioli; B. gladioli might have caused the three cases of early neonatal sepsis due to vertical or vaginal transmission. B. gladioli may be transmitted via environmental contamination, colonization, or person-to-person transmission in NICUs.
Shin et al. reported that B. gladioli should be considered an opportunistic pathogen in hospitalized patients undergoing invasive vascular diagnostic or therapeutic procedures. They also speculated that although the transmission route is unknown, it is most likely transmitted during invasive procedures via the patient's skin [14] . In the present study, all cases of nosocomial sepsis (n09) had a peripheral intravenous line and nasogastric catheter, two had an umbilical catheter, three had a central venous catheter, one had a peritoneal catheter, one had a thoracic catheter, seven were intubated, and three were treated with CPAP prior to positive blood culture results. As such, we think that B. gladioli may have caused sepsis in the NICU patients that underwent invasive procedures.
Boyanton et al. reported that B. gladioli isolate was susceptible to gentamycin, amikacin, ticarcillin-clavulanate, and ciprofloxacin [1] . Graves et al. reported that B. gladioli strains were susceptible to quinolones, aminoglycosides, and imipenem [7] . In the present study, antimicrobial susceptibility was 100 % for amikacin, gentamycin, imipenem, trimethoprimsulfamethoxazole, ciprofloxacin, and ceftriaxone. Antimicrobial resistance was 100 % for aztreonam, ceftazidime, and colistin and 71.4 % for piperacillin-tazobactam. The majority of the presented patients were treated with meropenem and gentamycin/amikacin ( Table 1 ).
The mortality rate in humans due to B. gladioli infection is unknown. Graves et al. reported four cases with B. gladioli infection that were susceptible to complement-mediated lysis of pooled human serum. The researchers concluded that the lack of mortality associated with B. gladioli infection, coupled with susceptibility to serum and lack of recognizable virulence-associated factors, suggests that this species has low pathogenic potential in humans [7] . In the present study, the overall in-hospital mortality rate was 21.4 % versus 7 % for B. gladioli infection; however, the neonate that died 14 days after positive blood culture results were obtained. The patient also had severe congenital heart malformation and died 6 h post-surgery. We think that this patient died due to his primary disease (atrioventricular septal defect and pulmonary stenosis) and/or surgical complications, not from B. gladioli sepsis. The course of B. gladioli infection in neonates is unknown. In the present study, the clinical course was moderate to severe, depending on the underlying critical diseases.
In conclusion, the present findings show that B. gladioli could be a cause of both early neonatal and nosocomial sepsis in NICUs. Invasive procedures and severe major congenital anomalies may be predisposing factors for B. gladioli bloodstream infection in neonates. Although it appears to have low pathogenic potential and an insidious clinical course in newborns, resistance patterns to antibiotics may be a potential problem. The lack of molecular identification methods is a limitation of the present study. B. gladioli should be a consideration in neonates with clinical sepsis and negative cultures. Additional research is needed for more definitive determination of the prognosis and mortality rate associated with B. gladioli infection in NICU patients.
